© 1991


Recent Trends and Progress

  • Gregory Gregoriadis
  • Anthony C. Allison
  • George Poste

Part of the NATO ASI Series book series (NSSA, volume 215)

Table of contents

  1. Front Matter
    Pages i-viii
  2. R. Bomford, M. Stapleton, S. Winsor
    Pages 25-32
  3. N. E. Byars, G. M. Nakano, M. Welch, A. C. Allison
    Pages 33-42
  4. Richard N. Hjorth, Geraldine M. Bonde, Elizabeth D. Piner, Kenneth M. Goldberg, Daniel M. Teller, Mark Hite et al.
    Pages 43-58
  5. Guy J. W. J. Zigterman, Andre F. M. Verheul, Harm Snippe
    Pages 59-75
  6. A. W. Heath, J. H. L. Playfair
    Pages 77-84
  7. D. E. S. Stewart-Tull
    Pages 85-92
  8. A. Bartoloni, M. G. Pizza, A. Covacci, D. Nucci, L. Nencioni, R. Rappuoli
    Pages 99-105
  9. M. A. Epstein
    Pages 107-112
  10. K-H. Hsu, M. Lubeck, S. Mizutani, R. Natuk, M. Chengalvala, P. Chanda et al.
    Pages 113-119
  11. P. Helena Makela, Helena Kayhty, Aino K. Takala, Heikki Peltola, Juhani Eskola
    Pages 121-135
  12. Norbert Dreifurst, Avrion Mitchison
    Pages 137-143
  13. Back Matter
    Pages 145-154

About this book


The success of vaccination in controlling infectious diseases is well documented. However, low profitability, expense and liability have hindered research and development of vaccines. Recently, increasing realization (enhanced by the AIDS pandemic) of the need to overcome such difficulties has led to steps being taken by national authorities, non-profit and commercial organizations to resolve them. This has been facilitated by developments in recombinant DNA techniques, the advent of monoclonal anti­ bodies and progress in the understanding of the immunological structure of proteins which have laid the foundation of a new generation of vaccines. Such vaccines are defined at the molecular level, can elicit immune responses controlling infectious organisms and are therefore potentially free of the problems encountered in conventional ones. Unfortunately, subunit and synthetic peptide vaccines are often only weakly or non­ inmunogenic. However, developments in both antigen production and immuno­ potentiation of weak antigens have opened new avenues with exciting prospects for vaccine design.


AIDS Antigen development diseases infectious disease proteins research vaccine

Editors and affiliations

  • Gregory Gregoriadis
    • 1
  • Anthony C. Allison
    • 2
  • George Poste
    • 3
  1. 1.School of PharmacyUniversity of LondonLondonUK
  2. 2.Syntex ResearchPalo AltoUSA
  3. 3.SmithKline Beecham PharmaceuticalsKing of PrussiaUSA

Bibliographic information